These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28892319)

  • 1. [Which antidiabetic agent in a patient with type 2 diabetes and heart failure ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Sep; 72(9):423-428. PubMed ID: 28892319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Fitchett DH; Udell JA; Inzucchi SE
    Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
    Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R
    BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
    Peters MN; Pollock JS; Rajagopalan S
    J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of oral antidiabetic medications in heart failure patients.
    Palazzuoli A; Ceccarelli E; Ruocco G; Nuti R
    Heart Fail Rev; 2018 May; 23(3):325-335. PubMed ID: 29359260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
    Arnold SV; Echouffo-Tcheugui JB; Lam CSP; Inzucchi SE; Tang F; McGuire DK; Goyal A; Maddox TM; Sperling LS; Fonarow GC; Masoudi FA; Kosiborod M
    Am Heart J; 2018 Sep; 203():25-29. PubMed ID: 30015065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
    Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
    Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
    Chiang CE; Ueng KC; Chao TH; Lin TH; Wu YJ; Wang KL; Sung SH; Yeh HI; Li YH; Liu PY; Chang KC; Shyu KG; Huang JL; Tsai CD; Hung HF; Liu ME; Chao TF; Cheng SM; Cheng HM; Chu PH; Yin WH; Wu YW; Chen WJ; Lai WT; Lin SJ; Yeh SJ; Hwang JJ
    J Chin Med Assoc; 2020 Jul; 83(7):587-621. PubMed ID: 32628427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure.
    Osuna PM; Brown SJ; Tabatabai LS; Hamilton DJ
    Methodist Debakey Cardiovasc J; 2018; 14(4):257-265. PubMed ID: 30788011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
    Ambrosio G; De Ferrari GM; Federici M; Filardi PP
    G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin in patients with type 2 diabetes mellitus and heart failure: a review.
    Kułaczkowska ZM; Wróbel M; Rokicka D; Gąsior M; Strojek K
    Endokrynol Pol; 2021; 72(2):163-170. PubMed ID: 33970481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes Mellitus and Heart Failure.
    Lehrke M; Marx N
    Am J Med; 2017 Jun; 130(6S):S40-S50. PubMed ID: 28526183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.